Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03092323 · ClinicalTrials.gov registry record · Phase 2
A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity
A Phase 2 study of Soft Tissue Sarcoma of the Extremity, sponsored by Sarcoma Alliance for Research through Collaboration.
- Active
- Registry status
- Phase 2
- Development phase
- 126
- Enrollment target
- 20
- Study locations
NCT03092323: Active Phase 2 study of Soft Tissue Sarcoma of the Extremity, sponsored by Sarcoma Alliance for Research through Collaboration.
NCT03092323 is a Phase 2 study of Soft Tissue Sarcoma of the Extremity that is active but no longer recruiting, run by Sarcoma Alliance for Research through Collaboration. The registered enrollment target is 126 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. The trial reports 20 study locations across 18 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03092323, a Phase 2 study of Soft Tissue Sarcoma of the Extremity, is active but no longer recruiting, sponsored by Sarcoma Alliance for Research through Collaboration.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 126 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label, multi-institutional phase II randomized study comparing neoadjuvant radiotherapy followed by surgical resection to neoadjuvant pembrolizumab with concurrent radiotherapy, followed by surgical resection and adjuvant pembrolizumab. The total duration of pembrolizumab will be one year in the experimental arm.
Primary Outcome
Disease recurrence is defined as clinically diagnosed or biopsy-confirmed recurrent sarcoma at a site distant to the primary tumor, including nodal metastasis, loco-regional recurrence, and death without documented recurrence.
Conditions Studied
Interventions
- DRUG Pembrolizumab
Study Locations (20)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Dana-Farber Cancer Institute - Boston
Pennsylvania
- University of Pennsylvania- Abramson Cancer Center - Philadelphia
- University of Pittsburgh (UPMC Hillman Cancer Center) - Pittsburgh
California
- University of California Los Angeles - Los Angeles
Florida
- Mayo Clinic- Florida - Jacksonville
Iowa
- University of Iowa Hospitals & Clinics - Iowa City
Kansas
- University of Kansas Medical Center - Kansas City
Maryland
- Johns Hopkins University - Baltimore
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2017-07-19 |
| Est. Completion | 2028-09-01 |
| Phase | Phase 2 |
What the registry record for NCT03092323 still lists
NCT03092323 is an interventional study that assigns participants to a tested intervention. The registered 126 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 1 condition, with Soft Tissue Sarcoma of the Extremity appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT03092323 names 20 study sites across 18 states, led by Massachusetts, Pennsylvania, California.
Frequently Asked Questions
What is clinical trial NCT03092323 about?
NCT03092323 is a clinical study titled "A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity". This is an open-label, multi-institutional phase II randomized study comparing neoadjuvant radiotherapy followed by surgical resection to neoadjuvant pembrolizumab with concurrent radiotherapy, followed by surgical resection and adjuvant pembrolizumab. The total duration of pembrolizumab will be one...
What is the current status of trial NCT03092323?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 126 participants. The study started on 2017-07-19. Estimated completion is 2028-09-01.
What conditions does trial NCT03092323 study?
This clinical trial studies the following conditions: Soft Tissue Sarcoma of the Extremity.
What interventions are being tested in trial NCT03092323?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT03092323?
This trial is sponsored by Sarcoma Alliance for Research through Collaboration, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03092323 being conducted?
This trial has 20 study locations across California, Florida, Iowa, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03092323's enrollment target sits among peer trials
126 556th of 2000 higher than 1,443 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01873131 · 126 participants · NA
A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn
- NCT02621645 · 126 participants · Phase 4
TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence
- NCT03838107 · 126 participants
Markers of Trajectory in Pediatric CRPS
- NCT03906422 · 126 participants · NA
Comparison of Patient-reported Pain After Initial Archwire Placement
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI